Cover Image
市場調查報告書

血管內皮層細胞生長因子B:開發中產品分析

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 368716
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
血管內皮層細胞生長因子B:開發中產品分析 Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H2 2016
出版日期: 2016年07月30日 內容資訊: 英文 65 Pages
簡介

本報告提供以血管內皮層細胞生長因子B為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

血管內皮層細胞生長因子B 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Alteogen Inc.
  • Clearside BioMedical, Inc.
  • CSL Limited
  • Eli Lilly and Company
  • Formycon AG
  • Regeneron Pharmaceuticals, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0431TDB

Summary

Global Markets Direct's, 'Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H2 2016', provides in depth analysis on Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted pipeline therapeutics.

The report provides comprehensive information on the Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
  • The report reviews Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Overview
  • Therapeutics Development
    • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Products under Development by Stage of Development
    • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Products under Development by Therapy Area
    • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Products under Development by Indication
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Products under Development by Companies
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Companies Involved in Therapeutics Development
    • Alteogen Inc.
    • Clearside BioMedical, Inc.
    • CSL Limited
    • Eli Lilly and Company
    • Formycon AG
    • Regeneron Pharmaceuticals, Inc.
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Drug Profiles
    • (aflibercept + nesvacumab) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (aflibercept + rinucumab) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (aflibercept + triamcinolone acetonide) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 2H-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aflibercept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aflibercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aflibercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSL-346 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ziv-aflibercept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Dormant Projects
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Discontinued Products
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Featured News & Press Releases
    • Jun 08, 2016: NICE draft recommendation on the use of aflibercept (EYLEA) for management of branch retinal vein occlusion goes against Royal College of Ophthalmologists' guidance
    • May 25, 2016: Regeneron Announces Important US Prescribing Information Clarification for EYLEA (aflibercept) Injection
    • Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion
    • Mar 01, 2016: Aflibercept in myopic choroidal neovascularization: Added benefit not proven
    • Feb 29, 2016: Formycon discloses details on second pipeline product - FYB203 is a biosimilar for Eylea (aflibercept)
    • Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration
    • Oct 30, 2015: Bayer Receives EU Approval for EYLEA for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization
    • Sep 25, 2015: Bayer's Eye Drug Recommended for EU Approval in Fifth Indication
    • Sep 18, 2015: Three-Year Results with EYLEA Show Sustained Improvement in Vision for People with Diabetic Macular Edema
    • Jul 21, 2015: NICE gives green light to aflibercept solution for treating serious eye condition
    • Jun 26, 2015: Bayer Receives Approval for EYLEA for the Treatment of Retinal Vein Occlusion in Japan
    • Jun 02, 2015: NICE Recommended Aflibercept Solution For Injection For Treating Serious Diabetic Eye Condition In Final Draft Guidance
    • May 06, 2015: Data presented at ARVO 2015 further showcase the real-world efficacy of EYLEA in UK clinical practice
    • Apr 01, 2015: New Phase 3 Study in China Confirms Vision Improvement for Patients with Wet Age-Related Macular Degeneration when Receiving Aflibercept Solution for Intravitreal Injection
    • Mar 25, 2015: EYLEA (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Retinopathy in Patients with Diabetic Macular Edema
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Alteogen Inc., H2 2016
  • Pipeline by Clearside BioMedical, Inc., H2 2016
  • Pipeline by CSL Limited, H2 2016
  • Pipeline by Eli Lilly and Company, H2 2016
  • Pipeline by Formycon AG, H2 2016
  • Pipeline by Regeneron Pharmaceuticals, Inc., H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top